Table 2.
Baseline Characteristics of Patients After Propensity Score Matching
| Characteristics | All Patients (n=156) | Non-Surgery (n=98) | Surgery (n=58) | χ2/t | P value |
|---|---|---|---|---|---|
| Age | 47.06 (10.69) | 48.01 (10.95) | 45.45 (10.13) | 1.45 | 0.149 |
| Sex | |||||
| Male | 123 (78.85%) | 76 (77.55%) | 47 (81.03%) | 0.27 | 0.709 |
| Female | 33 (21.15%) | 22 (22.45%) | 11 (18.97%) | ||
| T stage | |||||
| 1 | 84 (53.85%) | 50 (51.02%) | 34 (58.62%) | 0.85 | 0.426 |
| 2 | 72 (46.15%) | 48 (48.98%) | 24 (41.38%) | ||
| N stage | |||||
| 0 | 111 (71.15%) | 68 (69.39%) | 43 (74.14%) | 0.40 | 0.601 |
| 1 | 45 (28.85%) | 30 (30.61%) | 15 (25.86%) | ||
| Clinical stage | |||||
| I | 57 (36.54%) | 32 (32.65%) | 25 (43.10%) | 1.72 | 0.253 |
| II | 99 (63.46%) | 66 (67.35%) | 33 (56.90%) | ||
| Radiotherapy | |||||
| IMRTa | 113 (72.44%) | 75 (76.53%) | 38 (65.52%) | 2.21 | 0.163 |
| 2DRTb | 43 (27.56%) | 23 (23.47%) | 20 (34.48%) | ||
| Concurrent Chemotherapy | |||||
| No | 27 (17.31) | 21 (21.43) | 6 (10.34) | 3.13 | 0.093 |
| Yes | 129 (82.69) | 77 (78.57) | 52 (89.66) | ||
| Residualposition | |||||
| No | 141 (90.38%) | 84 (85.71%) | 58 (100.00%) | 9.10 | 0.014 |
| NPc | 11 (7.05%) | 10 (10.20%) | 0 (0.00%) | ||
| LNd | 3 (1.92%) | 3 (3.06%) | 0 (0.00%) | ||
| NP&LN | 1 (0.64%) | 1 (1.025) | 0 (0.00%) |
Note: Bold formatting indicates statistically significant.
Abbreviations: aIntensity modulated radiotherapy; b2-dimensional radiotherapy; cNasopharynx; dCervical lymph nodes.